S&P: Wyle Laboratories unchanged

Standard & Poor's said that its ratings and outlook on Wyle Laboratories Inc. (B+/negative) would not immediately be affected by press reports that the company is for sale.

The sale of the company likely would result in either a strengthened or weakened credit profile, depending upon the acquirer, however, because all of Wyle's funded debt is bank debt, all rated debt likely would be refinanced in the event of a sale and the rating withdrawn, the agency added.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.